Masimo (MASI) Stock

MASI, PEN, and VCYT from the Zacks Medical Instruments sector are good investment options due to their use of genAI, strategic growth, and solid financial health. However, challenges like geopolitical tensions and problems with wages and supplies could affect their future performance.

MASI, PEN, and VCYT from the Zacks Medical Instruments sector are good investment options due to their use of genAI, strategic growth, and solid financial health. However, challenges like geopolitical tensions and problems with wages and supplies could affect their future performance.

MAMO reports a 30.7% rise in non-GAAP operating income for the third quarter of 2024. The healthcare segment's revenues grew by 11.5%, contributing to the overall growth during this period of strategic changes.

While the revenue and earnings per share (EPS) for Masimo (MASI) provide insight into its performance for the quarter ending September 2024, it could be helpful to look at how these important figures stack up against Wall Street predictions and last year's results.

On Friday, Apple persuaded a federal jury that the smartwatches made by health monitoring tech company Masimo violate two of its design patents.

Masimo (MASI) has a strong track record of surprising with its earnings and currently has the right mix of factors that suggest it may exceed expectations in its upcoming quarterly report.

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI), a top global medical innovator, has announced the immediate addition of Timothy J. Scannell and Wendy E. Lane to its Board of Directors. With these new appointments, the Board will now have eight members. Quentin Koffey, the Lead Independent Director, expressed his happiness in welcoming Tim and Wendy, highlighting their impressive professional backgrounds.

No matter if you invest in value, growth, or momentum stocks, the Zacks Style Scores can help you identify strong stocks more easily. This is one of the key features of the Zacks Premium research service.

As of October 10, 2024, two stocks in the healthcare sector may be sending a serious alert to investors who consider momentum an important factor in their trading choices.